Acute liver failure due to regorafenib may be caused by impaired liver blood flow: A case report

Takaki Akamine, Koji Ando, Eiji Oki, Hiroshi Saeki, Yuichiro Nakashima, Yu Imamura, Kippei Ohgaki, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

7 引用 (Scopus)

抄録

Background/Aim: Regorafenib has been approved for treatment of patients with unresectable or recurrent gastrointestinal stromal tumors resistant to imatinib or sunitinib. However, regorafenib has severe side-effects, including acute liver failure. We describe the case of a patient with multiple liver metastases of a small intestinal stromal tumor who experienced acute liver failure while being treated with regorafenib. Case Report: A 50-year-old patient with an unresectable small intestinal stromal tumor resistant to prior treatment with imatinib and sunitinib was started on regorafenib, but experienced acute liver failure 10 days later. Plasma exchange and steroid pulse treatment improved her liver function. During liver failure, abdominal ultrasonography showed to-and-fro flow in the portal vein. Lactate dehydrogenase concentration was markedly elevated to 1633 U/l. These findings indicate that liver failure in this patient was due to impaired liver blood flow. Conclusion: Regorafenib may impair liver blood flow, inducing acute liver failure.

元の言語英語
ページ(範囲)4037-4042
ページ数6
ジャーナルAnticancer research
35
発行部数7
出版物ステータス出版済み - 7 1 2015

Fingerprint

Acute Liver Failure
Liver
Liver Failure
Gastrointestinal Stromal Tumors
Plasma Exchange
Portal Vein
L-Lactate Dehydrogenase
Ultrasonography
Neoplasms
Therapeutics
Steroids
regorafenib
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Acute liver failure due to regorafenib may be caused by impaired liver blood flow : A case report. / Akamine, Takaki; Ando, Koji; Oki, Eiji; Saeki, Hiroshi; Nakashima, Yuichiro; Imamura, Yu; Ohgaki, Kippei; Maehara, Yoshihiko.

:: Anticancer research, 巻 35, 番号 7, 01.07.2015, p. 4037-4042.

研究成果: ジャーナルへの寄稿記事

Akamine, T, Ando, K, Oki, E, Saeki, H, Nakashima, Y, Imamura, Y, Ohgaki, K & Maehara, Y 2015, 'Acute liver failure due to regorafenib may be caused by impaired liver blood flow: A case report', Anticancer research, 巻. 35, 番号 7, pp. 4037-4042.
Akamine, Takaki ; Ando, Koji ; Oki, Eiji ; Saeki, Hiroshi ; Nakashima, Yuichiro ; Imamura, Yu ; Ohgaki, Kippei ; Maehara, Yoshihiko. / Acute liver failure due to regorafenib may be caused by impaired liver blood flow : A case report. :: Anticancer research. 2015 ; 巻 35, 番号 7. pp. 4037-4042.
@article{e7d73ed8a62f45459c494ff2aac4cbba,
title = "Acute liver failure due to regorafenib may be caused by impaired liver blood flow: A case report",
abstract = "Background/Aim: Regorafenib has been approved for treatment of patients with unresectable or recurrent gastrointestinal stromal tumors resistant to imatinib or sunitinib. However, regorafenib has severe side-effects, including acute liver failure. We describe the case of a patient with multiple liver metastases of a small intestinal stromal tumor who experienced acute liver failure while being treated with regorafenib. Case Report: A 50-year-old patient with an unresectable small intestinal stromal tumor resistant to prior treatment with imatinib and sunitinib was started on regorafenib, but experienced acute liver failure 10 days later. Plasma exchange and steroid pulse treatment improved her liver function. During liver failure, abdominal ultrasonography showed to-and-fro flow in the portal vein. Lactate dehydrogenase concentration was markedly elevated to 1633 U/l. These findings indicate that liver failure in this patient was due to impaired liver blood flow. Conclusion: Regorafenib may impair liver blood flow, inducing acute liver failure.",
author = "Takaki Akamine and Koji Ando and Eiji Oki and Hiroshi Saeki and Yuichiro Nakashima and Yu Imamura and Kippei Ohgaki and Yoshihiko Maehara",
year = "2015",
month = "7",
day = "1",
language = "English",
volume = "35",
pages = "4037--4042",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

TY - JOUR

T1 - Acute liver failure due to regorafenib may be caused by impaired liver blood flow

T2 - A case report

AU - Akamine, Takaki

AU - Ando, Koji

AU - Oki, Eiji

AU - Saeki, Hiroshi

AU - Nakashima, Yuichiro

AU - Imamura, Yu

AU - Ohgaki, Kippei

AU - Maehara, Yoshihiko

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Background/Aim: Regorafenib has been approved for treatment of patients with unresectable or recurrent gastrointestinal stromal tumors resistant to imatinib or sunitinib. However, regorafenib has severe side-effects, including acute liver failure. We describe the case of a patient with multiple liver metastases of a small intestinal stromal tumor who experienced acute liver failure while being treated with regorafenib. Case Report: A 50-year-old patient with an unresectable small intestinal stromal tumor resistant to prior treatment with imatinib and sunitinib was started on regorafenib, but experienced acute liver failure 10 days later. Plasma exchange and steroid pulse treatment improved her liver function. During liver failure, abdominal ultrasonography showed to-and-fro flow in the portal vein. Lactate dehydrogenase concentration was markedly elevated to 1633 U/l. These findings indicate that liver failure in this patient was due to impaired liver blood flow. Conclusion: Regorafenib may impair liver blood flow, inducing acute liver failure.

AB - Background/Aim: Regorafenib has been approved for treatment of patients with unresectable or recurrent gastrointestinal stromal tumors resistant to imatinib or sunitinib. However, regorafenib has severe side-effects, including acute liver failure. We describe the case of a patient with multiple liver metastases of a small intestinal stromal tumor who experienced acute liver failure while being treated with regorafenib. Case Report: A 50-year-old patient with an unresectable small intestinal stromal tumor resistant to prior treatment with imatinib and sunitinib was started on regorafenib, but experienced acute liver failure 10 days later. Plasma exchange and steroid pulse treatment improved her liver function. During liver failure, abdominal ultrasonography showed to-and-fro flow in the portal vein. Lactate dehydrogenase concentration was markedly elevated to 1633 U/l. These findings indicate that liver failure in this patient was due to impaired liver blood flow. Conclusion: Regorafenib may impair liver blood flow, inducing acute liver failure.

UR - http://www.scopus.com/inward/record.url?scp=84937107472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937107472&partnerID=8YFLogxK

M3 - Article

C2 - 26124352

AN - SCOPUS:84937107472

VL - 35

SP - 4037

EP - 4042

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -